Provided by Tiger Fintech (Singapore) Pte. Ltd.

Adagene

2.04
+0.03001.49%
Volume:806.00
Turnover:1.62K
Market Cap:96.10M
PE:-2.75
High:2.04
Open:2.01
Low:2.01
Close:2.01
Loading ...

Adagene announces regulatory update on development plan for muzastotug

TIPRANKS
·
15 Jul

Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA

GlobeNewswire
·
15 Jul

Adagene Inc. Partners with ConjugateBio to Develop Novel Antibody Drug Conjugates

Reuters
·
08 Jul

BRIEF-Adagene Announces Up To $25 Million Strategic Investment From Sanofi

Reuters
·
01 Jul

Adagene Inc. Announces New Clinical Trial for Muzastotug in Advanced Solid Tumors Following $25 Million Strategic Investment by Sanofi

Reuters
·
01 Jul

Adagene Reports Promising ADG126 Study Results at ASCO

TIPRANKS
·
23 May

Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire
·
23 Apr

Adagene to Present at Stifel’s 2025 Virtual Targeted Oncology Forum

GlobeNewswire
·
07 Apr

Adagene Price Target Maintained With a $8.00/Share by HC Wainwright & Co.

Dow Jones
·
03 Apr

Adagene’s Promising Clinical Developments and Strong Financial Outlook Justify Buy Rating

TIPRANKS
·
03 Apr

Adagene Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.
·
26 Mar

Adagene Inc. Reports 2024 Financial Results and Progress

TIPRANKS
·
25 Mar

Adagene FY24 Adj. EPS $(0.51) vs $(0.21) YoY; Revenues $103,204

Benzinga
·
24 Mar

Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update

GlobeNewswire
·
24 Mar

Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit

GlobeNewswire
·
13 Mar

Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer

GlobeNewswire
·
27 Feb